hereditary angioedema – pharmaceutical daily

September 18, 2019 Off

NICE recommends Takhzyro injection as an option for preventing recurrent attacks of hereditary angioedema (HAE)

NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.

March 7, 2019 Off

Pharming Group net profit €25M boosted by Ruconest sales

By Dino Mustafić

Dutch Pharming Group N.V. was profitable at the net level in every quarter and for the year as a whole, with the total net profit for the year ended at €25.0 million, representing a net margin of 19% and well ahead of analysts’ forecasts.

March 29, 2018 Off

Shire reaches regulatory milestones for investigational hereditary angioedema (HAE) treatment Lanadelumab

By Dino Mustafić

European Medicines Agency (EMA) has validated Shire’s marketing authorization application (MAA) for its lanadelumab, which was also accepted by Health…